Navigation Links
Monsanto Executives to Discuss Company's Growth Drivers, Profit Goals at Investor Conferences in February
Date:2/4/2009

ST. LOUIS, Feb. 4 /PRNewswire-FirstCall/ -- On the heels of a strong start to fiscal 2009, Monsanto Company (NYSE: MON) executives will explain to investors this month where the company sees its opportunities for continued growth through the rest of this year and how it plans to achieve its goal of more than doubling its fiscal 2007 gross profit level by fiscal 2012.

Terry Crews, chief financial officer, and Carl Casale, executive vice president of strategy and operations, will address investors in separate presentations at two conferences later this month. Both Monsanto executives will provide an update on the company's business performance and expectations, strategic initiatives, product performance, research-and-development pipeline, and other business matters at these conferences:

Tuesday, February 10, 2009 - Terry Crews will be presenting at the Goldman Sachs 13th Annual Agricultural Biotech Forum in New York. Crews' presentation will begin at 2:30 p.m. eastern time.

Wednesday, February 18, 2009 - Carl Casale will be presenting at the 2009 Morgan Stanley Global Basic Materials Conference, also in New York. Casale's presentation will begin at 12:15 p.m. eastern time.

Presentation slides and simultaneous audio webcasts of the conference calls may be accessed by visiting the company's web site at http://www.monsanto.com/investors. Following the live broadcasts, Monsanto will archive the presentation slides and replays of the webcasts at the company's web site.

About Monsanto Company

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large-scale farmers to produce more from their land while conserving more of our world's natural resources such as water and energy. To learn more about our business and our commitments, please visit: www.monsanto.com.

Contact: Justin Gioia (314-694-4003)


'/>"/>
SOURCE Monsanto Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. Monsanto Company Signs Share Subscription Agreement With Devgen
3. Monsanto and Evogene Collaborate on Nitrogen Use Efficiency Research
4. Monsanto Company Sets Webcast and Analyst/Media Call for 2007 Fourth-Quarter and Fiscal-Year Financial Results
5. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
6. Science Magazine Recognizes Monsanto as Top Employer
7. Monsanto Company Executives Adopt 10b5-1 Trading Plans
8. Monsanto and Devgen Describe New Approach to Insect-Protection
9. Monsantos R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade
10. National Academy of Sciences Recognizes Monsantos Chief Technology Officer for Development of Agricultural Biotechnology
11. Monsanto Executives to Address Investor Conferences in February
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Kurzlehrgang mit Fokus auf Assay zum ... metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen dar   ... Wie ... Peretz , Scientific Director bei ImmuneCarta, einen Kurzlehrgang zu ... intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im Rahmen der jährlich ...
(Date:2/17/2017)... India , February 17, 2017 ... report "Biomarkers Market by Product (Consumables, Service), Type ... Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) ... the market is projected to reach USD 53.34 ... 2016, growing at a CAGR of 13.8% during ...
(Date:2/17/2017)... Feb. 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... its oral peptide drug candidates, PTG-100 and PTG-200, ... European Crohn,s and Colitis Organization (ECCO).  The ECCO ... Spain from February 15 – 18, ... data on Protagonist drug candidates PTG-100 and PTG-200. ...
(Date:2/16/2017)... and GREENWICH, Conn. , ... investment firm focused on venture growth investments in ... of Josh Richardson , M.D. to Managing ... in biotechnology companies.  He is a board observer ... roles in Longitude,s investments in Aimmune Therapeutics, Akebia ...
Breaking Biology Technology:
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):